Navigation Links
Skyline Diagnostics Establishes Research Collaboration With Janssen
Date:7/6/2011

ROTTERDAM, The Netherlands, July 6, 2011 /PRNewswire/ --


 

Skyline Diagnostics B.V. (Skyline), a biotechnology company focusing on development and marketing of gene signature-based diagnostic assays based in The Netherlands, today announced that it has signed a Research Agreement with Johnson & Johnson Pharmaceutical Research and Development division of Janssen Pharmaceutica N.V. (Janssen).  Under the agreement Skyline, using its proprietary knowledge and technologies in the area of genetic profiling and bioinformatics will work with Janssen to generate and analyze diagnostic information related to the use of an undisclosed, marketed compound. Under the terms of the agreement, Skyline will receive R&D funding and could receive payments on the achievement of certain research milestones. Financial details of the agreement were not disclosed.

"We are very pleased with extension of this exciting companion diagnostic program," said Henk Viëtor, CEO of Skyline Diagnostics, "this collaboration will provide both companies the opportunity to develop a unique personalized medicine approach to help identify patients at increased risk of side effects."

About Skyline Diagnostics BV

Skyline Diagnostic with its headquarters in Rotterdam, The Netherlands, develops and markets array-based diagnostic tests using gene signatures for personalized medicine. The company has successfully translated several important scientific discoveries into diagnostics. These products, called Profilers, are based on gene expression and offer a high additional clinical value. Skyline Diagnostics' Profilers will provide the clinician in-depth insight in the prognosis of individual patients and facilitate the treatment decision making process. The company has built strong collaborations with leading scientists and has strategic alliances with industrial partners for distribution and manufacturing, including a 'Powered by Affymetrix' partnership.

Website: http://www.skyline-diagnostics.com


'/>"/>
SOURCE Skyline Diagnostics B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011
2. GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics
3. Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips
4. Magellan Biosciences and Miacom Diagnostics Team Up to Enable Faster, Easier Identification of Pathogens as Part of Magellans End-to-End Suite of Microbiology Products Designed to Streamline Lab Workflow and Enable Better Treatment Decisions
5. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression to be Presented at the American Psychiatric Association Annual Meeting
6. Signal Genetics and Pronto Diagnostics Announce Distribution Agreement
7. Reportlinker Adds Molecular Diagnostics Markets
8. SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics
9. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
10. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
11. Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, Whats Hot and Whats Not , The
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... MultiMountTM weigh modules. These weigh modules are designed according to European Hygienic ... (NSF). , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce ...
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. ... pleased to report compelling safety and clinical data from its ... type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment ... ... establishing a complete safety profile at 6 months and showed ...
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, Inc., a ... administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer has ... to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and advance the ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):